Pharnext, a clinical-stage biopharma company developing drug combinations based on big genomic data and artificial intelligence (AI), and the University Hospital Institute Méditerranée Infection, devoted to infectious and tropical diseases in France, have partnered to research potential drug candidates to fight COVID-19 virus. The joint activities will focus on rapidly testing in vitro a number of already approved drugs that were previously identified by Pharnext as potential candidates for ...